Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2024-25 | Page 23

Amount In Taka

### 31. Other comprehensive income/(expense)

| Particulars | Note | 30 June 2025 | 30 June 2024 |
|---|---|---|---|
| Fair Value Gain/(loss) on Investment in listed shares | | 762 | - |
| **Total** | | **762** | **-** |

### 32. Earnings per share (EPS)

| Particulars | Note | 30 June 2025 | 30 June 2024 |
|---|---|---|---|
| (a) Earnings attributable to the owners of the Company | | 6,940,622,589 | 5,829,529,200 |
| (b) Weighted average number of shares outstanding during the year | | 446,112,089 | 446,112,089 |
| **Earnings per share (EPS)** | | **15.56** | **13.07** |

### 33. Net asset value (NAV) per share

| Particulars | Note | 30 June 2025 | 30 June 2024 |
|---|---|---|---|
| Total assets | | 73,247,246,604 | 69,344,022,640 |
| Less Total liabilities | | (16,162,610,737) | (17,441,119,760) |
| Less Non-controlling Interest | | (3,977,498,766) | (3,952,938,136) |
| **Equity attributable to the owners of the Company** | | **53,107,137,101** | **47,949,964,744** |
| Number of ordinary shares | | 446,112,089 | 446,112,089 |
| **Net Asset Value (NAV) per share** | | **119.04** | **107.48** |

### 34. Net operating cash flow per share (NOCFPS)

| Particulars | Note | 30 June 2025 | 30 June 2024 |
|---|---|---|---|
| Net cash generated from operating activities | | 7,222,586,070 | 8,364,466,317 |
| Number of ordinary shares | | 446,112,089 | 446,112,089 |
| **Net operating cash flows per share (NOCFPS)** | | **16.19** | **18.75** |

### 35. Reconciliation of net profit with cash flows from operating activities

| Particulars | Note | 30 June 2025 | 30 June 2024 |
|---|---|---|---|
| **Profit after tax** | | **6,998,869,709** | **5,866,771,470** |
| Adjustment to reconcile net profit to net cash provided by operating activities : | | | |
| **Non-cash/non-operating items:** | | **2,045,986,876** | **2,064,343,994** |
| Depreciation | | 1,742,820,265 | 1,742,540,614 |
| Amortization | | 274,197,654 | 251,269,517 |
| Deferred tax | | 19,007,698 | 20,832,192 |
| Exchange rate fluctuation (gain)/loss on foreign currency bank loan | | 64,095,449 | 87,504,854 |
| Dividend income | | (974,510) | (1,142,364) |
| (Profit)/loss on sale of fixed assets | | (34,934,945) | (16,375,521) |
| Effect of exchange rate changes on cash and cash equivalents | | (18,224,735) | (20,285,298) |
| **Changes in working Capital** | | **(1,822,270,515)** | **433,350,853** |
| (Increase)/decrease in inventories | | (1,468,346,144) | 4,822,226 |
| (Increase)/decrease in spares and supplies | | 97,021,175 | (66,598,606) |
| (Increase)/decrease in trade and other receivables | | 172,257,512 | (181,706,397) |
| (Increase)/Decrease in advance income tax | | (61,337,656) | (67,551,527) |
| (Increase)/decrease in loans, advances, deposits and prepayments | | (167,702,331) | 267,025,059 |
| Increase/(decrease) in gratuity & WPPF | | 143,515,444 | 375,815,634 |
| Increase/(decrease) in trade and other payables | | (688,953,291) | 149,398,479 |
| Increase/(decrease) in accrued expenses | | 51,909,689 | (23,034,442) |
| Increase/(decrease) in income tax payable | | 99,365,087 | (24,819,573) |
| **Net cash generated from operating activities** | | **7,222,586,070** | **8,364,466,317** |